Skip to content

Emotion Regulation Therapy as mechanism-targeted intervention for high distress disorders

Emotion Regulation Therapy as mechanism-targeted intervention for high distress disorders

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00036409
Enrollment
50
Registered
2025-03-27
Start date
2024-08-20
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorders and adverse childhood experiences

Interventions

Group 1: 24 sessions of Emotion Regulation Therapy, with self-monitoring, acquisition of attention-based and metacognitive skills for emotion regulation, and development of value-based actions as esse

Sponsors

MSH Medical School Hamburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Diagnosis of a depressive disorder (F32.x, F33.x) as primary disorder and treatment focus PHQ-9 score > 9 PTQ score > 35 K10 Distress Scale > 23 Presence of adverse childhood experiences (assessed with ACE-D) Sufficient proficiency in German

Exclusion criteria

Exclusion criteria: Outpatient psychotherapy within the past 2 years Initiation of new antidepressant medication within the 3 months prior to baseline assessment Dose adjustment of antidepressant medication within 4 weeks prior to baseline assessment Discontinuation of antidepressant medication within 4 weeks prior to baseline assessment Acute suicidality Current substance use disorder (except tobacco) Bipolar affective disorders Current post-traumatic stress disorder Lifetime diagnosis of borderline personality disorder Current psychotic symptoms Body Mass Index < 17.5 Severe physical impairments interfering with outpatient psychotherapy

Design outcomes

Primary

MeasureTime frame
Depressive symptoms (PHQ-9 score at three months follow-up)

Secondary

MeasureTime frame
Dropout, adherence (video rating), adverse effects (INEP score at post-treatment), clinician-rated depressive symptoms (HAMD-17 score three months after treatment), repetitive negative thinking (PTQ score at three months follow-up)

Countries

Germany

Contacts

Public ContactSebastian Trautmann

MSH Medical School Hamburg

sebastian.trautmann@medicalschool-hamburg.de+49 40 36 12 26 4-9321

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026